Curriculum Vitae

view Dr. Hatoum's presentation  
view interview video in Windows Media or RealMedia
read the written transcript of Dr. Hatoum's presentation
read the written transcript of the interview   
access the printable version of this page

Hind T Hatoum & Company
155 N Harbor Drive, # 1912
Chicago, IL 60601
Tel. 312-856-9432 / Fax. 312-856-9404
E-mail address: hthatoum@sbcglobal.net 

Current position 

June 1997  - present: Consultant - Specializes in the integration of Pharmacoeconomics and quality of life strategies in clinical trials and outcome research; analyses and interpretation of QOL and economic data in clinical trials; Global pricing strategy and impact; Marketing strategies; pharmacoeconomic modeling; new products break-even price calculation; identification of economic drivers in support of pricing new products; burden of illness, as well, as building pharmacoeconomic dossiers in support of new products’ registration and pricing. Research is conducted with emphasis on regulatory compliance and in response to the expectations of third party payers. 

Educational experience

• 1975-1980 Ph.D. Health Care Administration
  Minor: Public Administration
  University of Mississippi, University, MS
• 1972-1974 M. S. Pharmacology
  Northeast Louisiana University, Monroe, LA
• 1965-1970 B. S. Pharmacy
  Damascus University, Damascus, Syria

Certification

December 1986 Passed Foreign Pharmacy Graduate Equivalency Examination. Eligible for Pharmacy Licensure in over 40 states.

Professional experience

• G. D. Searle & Company, Skokie, Illinois
• Responsibilities and Major Accomplishments at GD Searle:
  • March 1995- June 1997: Senior Director, Pharmacoeconomics
    G. D. Searle & Company, Skokie, Illinois
  • February 1994- February 1995: Director, Pharmacoeconomics
    G. D. Searle & Company, Skokie, Illinois
• Joined GD Searle in February 1994 to re-establish the Pharmacoeconomics (PE) function. During tenure at Searle, the following was accomplished:
  • Recruited and mentored a multi-disciplinary research team in Pharmacoeconomics
  • Responsible for all PE and QOL activities in all phases of clinical development as well as community- based outcome research.
  • Initiated and successfully negotiated the inclusion of PE and QOL programs in all company’s therapeutic areas. Representatives of therapeutic areas involved are:
    • Arthritis- both OA and RA, pain, NSAID-induced gastropathy.
    • Cardiovascular- including hypertension as well as coronary artery diseases: unstable Angina, angina, revascularization, MI (oral anti-platelet program) and congestive
    • Anti-infectives
    • Congestive heart failure
    • Anti-HIV 
    • Stroke 
    • Female health
    • Oncology
    • Sepsis
    • Sleep
    • Alzheimer
    • Microvascular surgery
    • Benign prostate hyperplasia
  • Established and managed an independent budget and cost centers.
  • Established and maintained liaison with all company divisions including R&D, Biostatistics. 
  • Marketing, Product Planning, Franchises, Sales, Managed Care, International affiliates, Regulatory, Medical, and Compliance.
  • Established in-house capabilities to conduct pharmacoepidemiologic and burden of condition studies.
    Established and maintained liaison with opinion leaders throughout the globe.
  • Coordinated a stream of scientifically valid and peer-reviewed publications supporting the Company’s bottom line.
  • Three of the Company’s Pharmacoeconomic- sponsored research programs attracted the popular and lay press. More than 65 newspapers around the country published excerpts of findings. CNN aired reports on multiple occasions.
  • Developed several computerized and interactive PE programs using PE generated data for use with large third party payers as well as the individual physician.
  • Coordinated several company wide PE and QOL training programs.
  • Planned and allowed for appropriate PE and QOL regulatory strategies in several therapeutic areas.
  • Designed all PE programs on global basis with allowances for customization by Affiliates.
  • Ensured all programs complied with Good Laboratory Practice Standards and maintained the scientific integrity of programs.
  • Developed and coordinated a major PE/QOL program in several managed care organizations.
• April 1993- Jan. 1994 Director, Pharmacoeconomics
  CNS/Dermatology
  Schering-Plough International, Kenilworth, New Jersey
• June 1993-present Adjunct Associate Professor
  Department of Pharmacy Administration
  College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois
• January 1990 Assistant Professor
  Department of Pharmacy Administration
  College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois
• January 1991- April-1993 Assistant Professor
  Department of Pharmacy Practice
  College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois
• 1991-1993 Adjunct Visiting Assistance Professor
  Department of Clinical Pharmacy
  Welsh School of Pharmacy, University of Wales, Cardiff, UK
• Jan.1986-Dec.1989 Clinical Assistant Professor- Health Research Analyst
  Department of Pharmacy Practice, Hospital Pharmacy Service
  College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois
• 1983 – 1985 Lecturer
  College of Pharmacy, Department of Pharmacy Administration
  University of Illinois at Chicago, Chicago, IL
• May 1984 –Dec. 1985 Adjunct Assistant Professor - Research Analyst
  Department of Pharmacy Practice
  Hospital Pharmacy Services
  College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois
• July 1983 -April 1984 Research Associate
  Hospital Pharmacy Services
  University of Illinois at Chicago, Chicago, IL
• 1979- 1980 Research Assistant
  Department of Health Care Administration
  School of Pharmacy
  University of Mississippi, University, MS
• 1976 - 1978 Research Associate
  Department of Pharmacology
  School of Pharmacy
  University of Mississippi, University, MS
• 1975 - 1976 Senior Research Assistant
  Department of Pharmacology
  School of Pharmacy
  University of Mississippi, University, MS

Teaching experience (University of Illinois, Chicago)

• 1992 – 1993 Coordinator - Graduate Specialty in Pharmacoeconomics. Instructed graduate courses in Principles of Pharmacoeconomics and Applied Pharmacoepidemiology.
• 1990 - 1993 Instructor and Coordinator (AD300) Pharmacy Roles and Environment.
• 1990 - 1992 Instructor (AD393) - Marketing Pharmaceutical Services.
• 1990-1991 Coordinator (AD 491-Spring Quarter) - Graduate Seminars in Pharmacy Administration.
• 1988 - 1989 Program Coordinator for Administrative Residences in Hospital Pharmacy.
• 1986 - 1988 Team Teaching (PR 309)-Pharmacy Practice in Health Care Institutions.
• 1985 - 1986 Instructor (PR 380) - Special Project in Pharmacy Practice.
• 1983 - 1985 Instructor (AD 205) - Pharmaceutical Marketing.
• Instructor (AD 115-116) Health Economics.
• 1972-1974 Teaching Assistant. Division of Pharmacology and Toxicology, School of Pharmacy, Northeast Louisiana University, Monroe, LA. 

Editorial experience

• 1988 - 1993 Member, Editorial Advisory Board
  The Annals of Pharmacotherapy
  Section on Clinical Pharmacy Practice Administration
• 1992 Reviewer
  Journal of Social and Administrative Pharmacy
• 1988-1994 Reviewer
  American Journal of Pharmaceutical Education
• 1987- 1993 Reviewer 
  DICP: The Annals of Pharmacotherapy
• 1987 – Present Reviewer
  Journal of Pharmaceutical Marketing and Management
• 1986 –1993 Reviewer
  American Journal of Hospital Pharmacy
• 1981 - 1982 Reviewed and edited articles to be included in an Arabic version of the
  Child Health Encyclopedia
• 1975 - 1980 Reviewed and extracted marihuana and cocaine papers in the areas of pharmacology, health, sociology and psychology. Abstracts were included in the 1st and 2nd Annotated Marihuana Bibliographies (1964 to 1975, 1975 to 979) published by the Research Institute of Pharmaceutical Sciences, School of Pharmacy, University, MS.

Honors and professional societies

• Member of Phi Kappa Phi Society.
• Member of Rho Chi Pharmacy Honor Society.
• Member of Sigma Xi Research Society.
• Member of Who's Who Registry to Global Business Leaders.
• Member of the ASHP Research and Education Foundation, Research and Demonstration Grants Selection Panel (1991-1994).
• Member of the ASHP Research and Education Foundation Awards Program Selection Panel (1990-1994).
• Member of the American Association for the Colleges of Pharmacy (1990-1994).
• Member of the American Public Health Association (APHA).
• Member of the American Society of Hospital Pharmacists (ASHP).
• Member of the International Society on Pharmacoepidemiology (ISPE).
• Member of the Drug Information Association (1992-present).
• Member of the International Society of Pharmacoeconomics (1995-present).
• Member of the Illinois Council of Hospital Pharmacists (1985-1990).
• Member of the Northern Illinois Society of Hospital Pharmacists (1985-1990).
• Member of the Professional Affairs Committee of ICHP (1987-1990).

Civic responsibilities and activities

• Member of the interdisciplinary team reviewing access to drug therapy and services for Erie Family Neighborhood Health Clinics (1992-1993).
• Member of the interdisciplinary team reviewing access to drug therapy services for Winfield Moody Neighborhood Health Clinic (1992).
• Member of the interdisciplinary team reviewing drug therapy practices for indigent population seen at Cook County Hospital Outpatient Clinics (1992-1993).
• Invited Pharmacy representative for Elder Care Project sponsored by Illinois League of Women Voters (1991).
• Participant in Minority High School Student Research Apprentice Program, sponsored by The National Institutes of Health (1992). 
• Participant in Summer Urban high school students training programs (1990-1991).
• Leader for the Marketing of the Pharmacy Patient Bill of Rights to the Public and within the Profession (1992-1993).

Publication activities in refereed journals

• Hatoum HT, Keye WR Jr., Marrs RP, Walton SM, Marshall DC. A Markov Model of the Cost Effectiveness of a New Highly-Purified, Human-Derived FSH versus Follitropin-ß Using Comparative Clinical Trial Data. Manuscript submitted to Fertility & Sterility.
• Comparison of the HUI-III with SF-36 Preference Based Single Index in a Clinical Trial Setting. HT Hatoum, JE Brazier, KS Akhras, manuscript accepted for publication at Value Health, March 2004.
• Ware JE Jr., Keller SD, Hatoum HT, Kong SX. The SF-36 Arthritis-Specific Health Index (ASHI): I. Development and cross-validation of scoring algorithms. Medical Care 1999; 37(5): MS40-MS50, Supplement.
• Keller SD, Ware JE Jr., Hatoum HT, Kong SX. The SF-36 Arthritis-Specific Health Index (ASHI): II. Tests of validity in four clinical trials. Medical Care 1999; 37(5): MS51-MS60, Supplement.
• Kosinski M, Keller SD, Ware JE Jr., Hatoum HT, Kong SX. The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis. Relative validity of scales in relation to clinical measures of arthritis severity. Medical Care 1999; 37(5): MS23-MS39, Supplement.
• Kosinski MA, Keller SD, Hatoum HT, Kong SX, Ware JE Jr. The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis. Tests of data quality, scaling assumptions and score reliability. Medical Care 1999; 37(5): MS10-MS22, Supplement.
• Mendelson WB, Hatoum HT, Kong SX, Wong JM, Kania CM. Insomnia and its Impact: A Survey of Enrollees at Five U.S. Managed Care Organization. Medicine & Behavior 2(1): 10-11 (1999).
• Kong SX, Hatoum HT, Zhao SZ, Agrawal NM, Geis SG. Prevalence and Costs of Hospitalizations for Gastrointestinal Complications Related to Peptic Ulcer Disease and Hemorrhage: Comparisons between Two National Databases. Am J Man Care 4(3): 399-409 (1998). 
• Hatoum HT, Kania CM, Kong SK, Wong JM, Mendelson WB. Prevalence of Insomnia: A Survey of the Enrollees at Five Managed Care Organizations. Am J Man Care 4 (1): 79-86 (1998).
• Hatoum HT, Kong SX, Kania CM, Wong JM, Mendelson WB. Insomnia, Health-Related Quality of Life and Health Care resource Consumption: A Study of Managed Care Organization Enrollees. Pharmacoecon. 14(6): 629-637 (1998).
• Miwa LJ, Jones JK, Pathiyal A, Hatoum HT. Value of Epidemiologic Studies in Determining the True Incidence of Adverse Events: The Nonsteroidal Anti-inflammatory Drug Story. Arch Intern Med. 157(18): 2129-2136 (1997).
• Simon LS, Hatoum HT, Bittman RM, Archambalt WT, Polisson RP. Risk Factors for Serious Nonsteroidal-induced Gastrointestinal Complications: Regression Analysis of the MUCOSA Data. Fam Med. 28:204-210 (1996).
• Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal Tract Complications of Nonsteroidal anti-inflammatory Drug Treatment in Rheumatoid Arthritis: A Prospective Observational Cohort Study. Arch Intern Med.156: 1530-1536 (1996).
• Lundquist SC, Hatoum HT, Hutchinson RA, Kong SX. A Comparative Profile of Clinical Pharmacy Activities for Pharmacotherapists and Residents in a University Hospital. Pharmacy practice Management Quarterly, 16(3): 35-41 (1996).
• Kong SX, Salmon JW, Barrenbaum L, Hatoum HT, Hutchinson RA. Issues and Concerns of Managed Care Pharmacy Directors: Results of a National Survey. J Man care Farm, 1(12): 116-120 (1995).
• Grussing, PG, Hatoum, HT, and Zaborniak, G. Pharmacy Satisfaction with Drug Wholesaler Services: A Regional Study. Journal of Pharmaceutical Marketing & Management, 8(3): 85-111 (1994).
• Hatoum, HT, Schumock, GT, and Kendzierski, DK. Meta-Analysis of Controlled Trials of Drug Therapy in Mild Chronic Asthma: The Role of Inhaled Corticosteroids. The Annals of Pharmacotherapy, 28(11), 1285-1289 (1994).
• Hatoum, HT, and Freeman, RA. The Use of Pharmacoeconomic Data in Formulary Selection. Topics in Hospital Pharmacy Management, 13(4): 47-53 (1994).
• Hatoum, HT, and Akhras, K. 1993 Bibliography: A 32-Year Literature Review on the Value and Acceptance of Ambulatory Care Provided by Pharmacists. The Annals of Pharmacotherapy, 27(9): 1106-1119 (1993).
• Hatoum, HT, Lewis, RK, Lundquist, S, Kendzierski, DL. Evaluation of a Pharmacy Resident Inpatient On-Call Program. American Journal of Pharmaceutical Education, 57(3): 238-241 (1993). 
• Tang. I, Vrahnos, D, Hatoum, HT, Lau, A. Effectiveness of Clinical Pharmacist Intervention in a Hemodialysis Unit. Clinical Therapeutics, 15(2): 459-464 (1993).
• Hatoum, HT, Witte, KW, Hutchinson, RA. Patient Care Contributions of Clinical Pharmacists in Four Ambulatory Care Clinics. Lippincott's Hospital Pharmacy, 27(3): 204-209 (1992).
• Stubbings, J, Hatoum, HT. The Medicaid Pharmaceutical Access and Prudent Purchasing Act: A Review and Analysis of its Impact on Managed Care Pharmacy. Journal of Pharmacy Practice, 5(2): 86-96 (1992).
• Hatoum, HT, Hutchinson, RA, Manasse Jr., HR. Pharmacy Agenda for Change: The Time Is Now. Lippincott's Hospital Pharmacy, 27(): 768-773 (1992).
• Cousins, D, Hatoum, HT. The Development of a Computerized Quality Assurance System for Clinical Pharmacy. Int. J Pharm Practice, 1:86-89 (1991).
• Hatoum, HT, Lewis, RK. Choosing Antibiotics in the Era of Assessment and Accountability: Focus on Cefazolin, P&T, 16(5): 409-421 (1991).
• Kraus, DM, Stile, I, Hatoum, HT. Multilevel Model to Assess Appropriateness of Pediatric Serum Drug Concentrations. American Journal of Diseases of Children, 145:1171-1175 (1991).
• Kraus, DM, Stifter, J, Hatoum, HT. An Emergency Medication Education Program for Pediatric Intensive Care Nurses. Am J Hosp Pharm, 48(1): 97-101, (1991).
• Hatoum, HT, Vlassess, P. Focus on Patient Outcome and the Future Practice of Pharmacy. DICP: The Annals of Pharmacotherapy, 25(2): 208-210 (1991).
• Hatoum, HT. Megatrends a la Pharmacy: Potential and Promise. Hospital Pharmacy, 25(9): 825-829, (1990).
• Hutchinson, RA, Lewis, RK, Hatoum, HT. Inconsistencies in the Drug Use Process. DICP: The Annals of Pharmacotherapy, 24(6): 633-636 (1990).
• Hatoum, HT. Microcost Analysis of Inpatient Dispensing and Administration of Oral Solids. American Journal of Hospital Pharmacy, 47:800-805 (1990).
• Hatoum, HT, Witte, KW, and Sherman, JA. The Assessment of Surveyors Criteria for Drug Use in One LTC Facility. Journal of the Geriatric Drug Therapy, 4(4): 95-109 (1990).
• Hutchinson, RA, Hatoum, HT, Kolinski, R, and Riley, D. Use of Pharmacy Personnel to Positively Impact Hospital Finances. Hospital Formulary, 24(8): 450-53 (1989).
• Hatoum, HT, Biedron G, Witte, KW, and Hutchinson, RA. Updating the Costs of Preparing Small Volume Injections. Am J Hosp Pharm, 46:268 (1989).
• Hatoum, HT, Hutchinson, RA, Elliott, LR, and Kendzierski, DL. Physicians' Review Significant Interventions by Clinic Pharmacists in Inpatient Care. Drug Intelligence & Clinical Pharmacy, 22(12): 980-982 (1988). 
• Bertsch, KE, Hatoum, HT, Willett, M, and Witte, KW. Cost-Justification of Clinical Pharmacy Services on a General Surgery Team: Focus on Diagnosis-Related Group Cases. Drug Intelligence & Clinical Pharmacy, 22(11): 906-910 (1988).
• Hatoum, HT, Hutchinson, RA, Elliott, LR, and Eck, T. Microcost Analysis of the Prescription Dispensing Process in an Outpatient Pharmacy. Am J Hosp Pharm, 45(6): 1328-1332 (1988).
• Hatoum, HT, Hutchinson, RA, Witte, KW, and Newby, GP. Evaluation of the Contribution of Clinical Pharmacists: Inpatient Care and Cost Reduction. Drug Intel & Clin Pharm. 22(3): 252-259 (1988).
• Hutchinson, RA, Hatoum, HT, and Witte, KW. Managing Patient Oriented Pharmacy Services - Challenges and Solutions. Current Concepts in Hosp Pharm Manage, 10 (1):7-13 (1988).
• Hatoum, HT, Smith, MC. Identifying Patterns of Professional Socialization for Pharmacists during Pharmacy Schooling after One Year in Practice. Am J Pharm Edu. 51 (spring): 7-17(1987).
• Davis, WM, and Hatoum, HT. Comparison of Stimulants and Hallucinogens on Shuttle Avoidance in Rats. General Pharmacology. 18(2): 123-128 (1987).
• Hutchinson, RA, and Hatoum, HT. The Need for and Methods of Cost-Justifying Hospital Pharmacy Services. J Pharm Mark Manage, 2(1): 115-124 (1987).
• Witte, KW, Hatoum, HT and Hoon, TJ. Contribution of Clinical Pharmacists to the Cefazolin Utilization. Hosp Formulary, 22(August): 737-741 (1987).
• Davis, WM, Hatoum, HT, and Waters, WI. Toxicity of MDA (3,4-Methylendio-xyamphetamine) Considered for Relevance to Hazards of MDMA (Ecstasy) Abuse. Alcohol and Drug Research, 7:123-34 (1987).
• Witte, KW, and Hatoum, HT. Modern Health Care Delivery System and the Pharmacist. Hospital Therapy, 11(11): 87-101 (1986).
• Hatoum, HT, Catizone, C, Hutchinson, RA and Purohit, A. Documentation of the Value and Acceptance of Clinical Pharmacy - A Review of the Pharmacy Literature. Drug Intel Clin Pharm, 20:33-48 (1986).
• Hatoum, HT, Witte, KW, Biedron, GT, and Hutchinson, RA. A Microcosting Method for Small Volume Parenterals. Am J Hosp Pharm, 43:348-354 (1986).
• Hutchinson, RA, Hatoum, HT, and Witte, KW. Editorial: A Debate for Long Term Survival Strategy for the Pharmacy Profession. Drug Intel Clin Pharm, 19:655-6 (1985).
• Hatoum, HT, and Smith, MC. Views of Pharmacy Students and Practitioners toward Tranquilizer Use. J Social Admin Pharm, 1(2) 65-70 (1983).
• Hatoum, HT, and Smith, MC. Orientation of Pharmacy Students and Practitioners toward Work, Family and Desired Professional Qualities. Contemp Pharm Pract, 5(2): 102-6 (1982).
• Hatoum, HT, Smith, MC, and Sharp, TR. Attitudes of Pharmacy Students toward Psychosocial Issues in Health Care. Social Science& Med, 16:1239-41 (1982).
• Davis, WM, Hatoum, HT, and Hatoum, NS. Methoxyamphetamines and Fenfluramine Compared to Amphetamine for Antagonism of Electroshock Seizures. Res Commun Subs Abuse, 3(3): 297-305 (1982).
• Smith, MC and Hatoum, HT. Opinions on Appropriateness of Psychotropic Drugs Ads. J Pharm Market & Media, 7(3): 131-135 (1979).
• Hatoum, HT and Davis, WM. Motility Effects of Amphetamine and 4-Methoxyamphetamine (PMA): Interaction with Agents Altering Central Neuromediators. Res Commun Psycho Psychiat Behav, 3(4): 325-334 (1978).
• Davis, WM, Hatoum, HT, and Waters, IW. Interactions of Catecholaminergic Receptor Blockers with Lethal Doses of Amphetamine or Substituted Amphetamines in Mice. Res Commun Chem Pathol Pharmacol, 21(1): 27-36 (1978).
• Davis, WM, Bedford, JA, Buelke, JL. Guinn, MM, Hatoum, HT, Waters, IW, Wilson, MC and Braude, MC. Acute Toxicity and Gross Behavioral Effects of Amphetamine, Four Methoxyamphetamines and Mescaline in Rodents, Dogs and Monkeys. Toxicol Appl Pharmacol, 45:49-62 (1978).
• Davis, WM, Waters, IW, Hatoum, HT, Buelke, JL, and Braude, MC. Triphasic Dose-Lethality Relationship for Amphetamine and Certain Ring-Substituted Amphetamines in Isolated or Aggregated Mice. Res Commun Chem Pathol Pharmacol, 17:575-582 (1977).

Reports

• Hind T Hatoum and Mick Kolassa. Global Pricing Strategies in a Changing Environment. Situational Analysis & Recommendations. H T Hatoum & Company, June 2000.
• Hind T. Hatoum. The Growing Role of QOL Assessments in Drug Development and Evaluation. Spectrum Life Sciences, Decision Resources, Inc. June 2000.

Book chapters

• Hatoum HT, Valuck RJ. Drug Use and the Health Care System. Pharmaceutical Care. CH Knowlton and RP Penna (Eds). Chapman & Hall, NY, pp.68-94 (1996).
• Davis, WM, Hatoum, HT, Smith, SG, and Braude, MC. Use of Unconditioned and Conditioned Behaviors in Evaluating Possible Hallucinogenic Agents. Psychopharmacology of Hallucinogens. RC Stillman and RE Willette (Eds.), Pergamon Press, NY, pp. 181-206, (1978).

Book reviews

• Essentials of Pharmacy Management. By Tootelin and Gaedeske. Mosby-Year Book, Inc., publisher, March 1992.
• Financial Management for Pharmacists: A Decision-Making Approach. By Norman V. Carrol, Lea & Febiger publisher, Philadelphia, 1991. Published in Journal of Pharmacy Technology, Volume 7, December 1991.
• How to Evaluate Progressive Pharmacy Services. By McKay, AB, Hepler, CD, Knapp, DA. American Society of Hospital Pharmacy Publication, 1988. Review was published in Drug Intel Clin Pharm, 1988.
• Small Comfort - A History of the Minor Tranquilizers. By Smith, MC, Praeger Special Studies. Praeger Scientific, 1985.
• Hatoum, HT, Hutchinson, RA, Lambert, BL. OBRA 90: Patient Counseling – Enhancing Patient Outcomes, C.E. program published in U.S. Pharmacist in 1993 sponsored by NABP and Glaxo Inc. (1992).

Other publications

• Hatoum, HT, Pharmacy Patient's Bill of Rights. U.S. Pharmacist, 17(5): 60-68 (May 1992).
• Hatoum, HT. Challenges for Tomorrow's Pharmacist. U.S.Pharmacist, 17(1): 50-54 (January 1992).
• Hatoum, H.T. Megatrends in Pharmacy: Potential & Promise. Pharmacy Business. (June 1991). A repeated publication from an earlier article published by Lippincott's Hospital Pharmacy.
• Hatoum, HT. The Social and Economic Impact of Inappropriate Drug Therapy. Proceedings from the 3rd Annual Focus on Illinois Clinicians: Pharmaceutical Care as an Issue of Public Policy. (UIC Publication, 1992).
• Hatoum, HT. Managed Care - Should Pharmacists Really Care? Drug Topics, 35 (11): 67-75 (1991), UIC Sponsored CE Program.
• Hatoum, HT. The Multidisciplinary Update on cost-effective Usage - Interview. Drug Utilization Review, 4(11): 141-156 (1988).
• Hatoum, HT. Research Profile for One Department. Profiles in Hosp Pharm (spring 1989).
• Hatoum, HT. Inpatient Cost Reduction - Comments/Replies. Drug Intel Clin Pharm, 22(2): 730 (1988).
• Hatoum, HT, Sherman J. and Witte, KW. Reducing the Incidence of Inappropriate Drug Therapy and Drug Costs in Long Term Care Facilities. A grant final report submitted to Illinois Department of Public Aid (September 1986).
• Hutchinson, RA, and Hatoum, HT. Why Pharmacy Needs to Microcost Small Volume Parenterals. Microlink (February 1986).
• Hatoum, HT. Commentary to Trends and Issues in Pharmacy Practice - Building a Retail Management Support System. By Gladson TR. Drug Topics (May 5 1986).
• Hatoum, HT. The Development of the Professional Role of the Pharmacist during various Stages of Socialization. Ph.D Dissertation, University of Mississippi (1980).
• Davis, WM, Hatoum, HT, and Smith, SG. Hazards and Abuse Liability of Various Drugs. Annual Report 1977-1978 (Contract No. ADM-45-74-107). Submitted to the National Institute on Drug Abuse, Division of Research.
• Davis, WM, Waters, IW, Hatoum, HT and Smith, SG. Hazards and Abuse Liability of Various Drugs. Annual Report 1976-1977 (Contract No. ADM-45-74-107). Submitted to the National Institute on Drug Abuse, Division of Research.
• Hatoum, HT. The Role of Acetylcholine in Electroshock Seizure in the Rat. MS Thesis, Northeast Louisiana University (1974).

Presentations

• Hatoum HT, Walton SM. A cost-effectiveness model of the economic impact of oxandrolone versus megestrol acetate in cancer patients with involuntary weight loss. Submitted to 6th Multinational Association of Supportive Care in Cancer / International Society for Oral Oncology (MASCC/ISOO, Miami Beach, FL. June 24-27, 2004.
• Hatoum HT, Pickard AS, Keye WR Jr., Marrs RP, Marshall DC. Quality of life analysis based on a randomized quality of life efficacy, safety and tolerability study of Bravelle+Repronex vs. Gonal-F in controlled ovarian hyperstimulation for In Vitro fertilization. Abstract submitted to American Society for Reproductive Medicine (ASRM) Conference, Philadelphia, Pennsylvania, October 16-20th, 2004. 
• Hatoum HT, Keye WR Jr., Marrs RP, Walton SM, Marshall DC. A Markov Model of the Cost Effectiveness of Mixed Protocol vs. rFSH Based on a Randomized Quality of Life, Efficacy, Safety and Tolerability (QUEST) Study of Bravelle® + Repronex® vs. Gonal-F® in Controlled Ovarian Hyperstimulation for In Vitro Fertilization. Abstract submitted to American Society for Reproductive Medicine (ASRM) Conference, Philadelphia, Pennsylvania, October 16-20th, 2004. 
• Hatoum HT, Pickard AS, Ottery FD. Use of the Patient-Generated Subjective Global Assessment (PG-SGA) to predict rate of hospitalization for cancer patients with involuntary weight loss (IWL): Role for Standardized Assessment, Early Intervention, and Oxandrolone. Mechanisms and Treatment of Cancer-Related Symptoms. MD Anderson Cancer Center. February 20-22, 2004.
• Hatoum HT, Pickard AS, Ottery FD. A predictive model of hospitalization and potential cost savings associated with oxandrolone in cancer patients with involuntary weight loss. (Abstract 3843). 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), New Orleans, LA. June 5-June 8, 2004.
• Hatoum HT, Keye WR Jr., Marrs RP, Walton SM, Marshall DC. A Markov Model of the Cost Effectiveness of a New Highly-Purified, Human-Derived FSH versus Follitropin-ß Using Comparative Clinical Trial Data. Abstract presented at the 59th Annual Meeting of the American Society for Reproductive Medicine, October 11-15, 2003, San Antonio, Texas.
• Brazier JE, Hatoum HT, Akhras KS, Boyer JG. Comparison of the Responsiveness of the SF-6D Index and the HUI-III in Patients with Coronary Artery Disease. Oral Presentation at ISOQOL 2002 Annual Meeting.
• HT Hatoum, JE Brazier, KS Akhras. Comparison of the HUI-III with SF-36 Preference Based Single Index in a Clinical Trial Setting. Abstract presented at Medical Decision Making Society Meeting in San Diego, CA on October 2001.
• Hatoum HT, Brazier J, Akhras K, Tooley J, Boyer J. Comparison between Investigator and Patient’s Global Health Assessments Using Calculated HUI-III and SF-36 Utility Values. Abstract presented at ISPOR International Meeting in Cannes, France on November 2001.
• Hatoum HT. Prescription Drug Benefit for the Elderly. Issues and Considerations. Presented to the Michigan State Legislators, Lansing, Michigan, March 14, 2001.
• Hatoum HT. The Pharmaceutical Industry / What the Debate Is All About? Presented to the Illinois State Legislators, Springfield, Illinois, November 29, 2000.
• Hatoum HT. Prescription Drug Benefit for the Elderly / What the Debate Is All About? Presented to the Illinois State Legislators, Schaumburg, Illinois, October 3, 2000.
• Mendelson WB, Wong JM, Kania CM, Kong SX, Hatoum HT. Insomnia in Managed Care Organization Patients: Use of Hypnotics, and Medical Care Utilization. Presented at Association of Professional Sleep Societies, New Orleans, Louisiana, June 18-23, 1998.
• Zhao SZ, Hatoum HT, Hubbard RC et al. Effect of Celecoxib, a Novel COX-2 Inhibitor, on Health-Related Quality of Life of Patients with Osteoarthritis of the Knee. Arthritis & Rheumatism, abstract supplement for ACR 61st National Scientific Meeting (Washington, DC), Nov. 8-12, 1997 (pS88).
• Hatoum HT, Wong JM, Kong SX, Kania CM, Mendelson WB. Impact of Insomnia on 
  Health-Related Quality of Life of Managed Care Organizations Enrollees. Fourth Annual Conference of the International Society for Quality of Life Research. Vienna, Austria, Nov 5-9, 1997.
• Mendelson WB, Hatoum HT, Kania CM, Kong SX, Wong JM. Insomnia and its Impact: A Survey of Enrollees at Five US Managed Care Organizations. Presented at The American Psychiatric Association Meeting, San Diego, California, May 17-22, 1997. 
• Jones Jk, Miwa L, Pathiya A, Hatoum HT. Value of Epidemiologic Studies in Determining the Incidence of Adverse Events: The NSAID Story. Presented at the American Society for Clinical Pharmacology and Therapeutics, San Diego, CA, March 5-7, 1997.
• Zhao SZ, Kong SX, Hatoum HT, Gersh GE. Hospitalizations Related to Leiomyma: Estimate from a Nationwide Hospital Discharge Database. Presented at the 13th International conference on Pharmacoepidemiology. Lake Buena Vista, Florida, August 24-27, 1997.
• Zhao SZ, Kong SX, Hatoum HT, Gersh GE. Hospital Experience of Endometriosis Based on the HCUP Database. Presented at the 13th International Conference on Pharmaco-epidemiology . Buena Vista, Florida, August 24-27,1997.
• Kong SX, Agrawal NM, Geis SG, Hatoum HT. Proportions of hospitalizations Related to Upper Gastrointestinal Complications and Associated Reimbursements: Data from National Hospital Discharge and Employer- Group Claims Databases. Presented at the Annual Meeting of the American Gastroenterological Association at Digestive Disease Week (DDW). Washington, DC, May 11-14, 1997.
• Mendelson WB, Hatoum HT, Kania C, Kong SX, Wong J. Insomnia and its Impact: A Survey at Five US Managed Care Organizations. Presented at the Annual Meeting of the American Psychiatric Association. San Diego, California, May 17-22, 1997.
• Ware JE, Keller SD, Hatoum HT, Kong SX. Development of an Arthritis-Specific SF-36 Health Index. Presented at the 19th ILAR Congress of Rheumatology. Singapore, June 8-13, 1997.
• Hatoum HT, Ware JE, Keller SD, Kong SX, Hurley SM, Bocanegra TS. Effect of Diclofenac and Fixed Combinations of Diclofenac and Misoprostol in Health-Related Quality of Life In-Patients with Osteoarthritis. Presented at the 19th ILAR Congress of Rheumatology, Singapore, June 8-13, 1997.
• Ware JE, Kosinski M, Hatoum HT, Kong SX. Psychometric Properties of the SF-36 Health Survey as a Generic Outcome Measure in Clinical Trials of Patients with Arthritis. Presented at the 19th ILAR Congress of Rheumatology, Singapore, June 8-13, 1997.
• Ware JE, Kosinski M, Hatoum HT, Kong SX. The SF-36 Health Survey as a Generic Measure in Clinical trials of Patients with Osteo- and Rheumatoid Arthritis: tests of Data Quality, Scaling Assumptions and Score Reliability. Presented at the 60th National Scientific Meeting of the American College of Rheumatology. Orlando, Florida, October 18-22, 1996. Abstract Published in Arthritis & Rheumatism, 39(9) S258 (1996).
• Ware JE, Keller SD, Hatoum HT, Kong SX. An Arthritis-Specific SF-36 Health index: 
  Development of a Cross-Validation in relation to Changes in Disease Severity. Presented At the 60th National Scientific meeting of the American College of Rheumatology. Orlando, Florida, October 18-22, 1996. . Abstract Published in Arthritis & Rheumatism, 39(9) S528 (1996).
• Hatoum HT, Ware JE, Keller SD, Kong SX, Kuss ME, Bocanegra TS. Effect of Oxaprozin and Nabumetone on Health-Related Quality of Life of Patients with Osteoarthritis of the Knee. Presented at the 60th National Scientific Meeting of the American College of Rheumatology. Orlando, Florida, October 18-22, 1996. Abstract Published in Arthritis & Rheumatism, 39(9) S225 (1996).
• Ware JE, Hatoum HT, Keller SD, Kong SX, Geis GS, Ball JA, Bocanegra TS, Hurley SM, Archambalt WT. Quality of Life of Rheumatoid Arthritis Patients Given Fixed Combinations of Diclofenac and Misoprostol or Diclofenac Alone. Presented at the EULAR 96 IX Symposium. Madrid, Spain, October 7-10, 1996.
• Ware JE, Hatoum HT, Keller SD, Kong SX, Archambalt WT. Quality of Life of Rheumatoid Arthritis Patients Given Fixed Combinations of Diclofenac and Misoprostol or Diclofenac Alone. Presented at the Annual Meeting of the American Gastroenterological Association at the Digestive Disease Week (DDW). San Francisco, California, May 19-22, 1996. Abstract Published in Gastroenterology, (110): A291 (1996).
• Hatoum HT. Insomnia. Quality of Life and Economic Consequences. A Community Based Study of Managed Care Enrollees. Presented at the American Group Practice Association Annual Outcome Meeting. San Francisco, California, July 18, 1996. 
• Hatoum HT. Insomnia. Quality of Life and Economic Consequences. Presented at IBC Sleep Disorder Conference. San Francisco, California, July 18, 1996. 
• Simon LS, Polisson RP, Hatoum HT, Bittman RM. Risk Factors for Serious NSAID-Induced GI complications: The risk-Reduction of Misoprostol Therapy in the Individual “At-Risk” Patient. Presented at the American College of Rheumatology National Scientific Meeting. San Francisco, California, October 1995.
• Hatoum HT, Panel Discussant: Critical Issues in the Conduct of Pharmacoeconomics, DIA Annual Meeting, June 27, 1995.
• Invited Speaker Pharmacy & Healthcare - An Agenda for Change. Session on Pharmacy Practice. NAPB 's 88th Annual Meeting, Salt Lake City, Utah, May 5, 1992.
• Invited Speaker NABC/AACP District IV Meeting, Pharmacy Patient Bill of Rights. 
  Chicago, IL, November 1992.
• Fish, D, Danziger, L, Novak, R, Hatoum, HT. Pharmacoeconomic evaluation of the Antimicrobial Therapy of Bacteremia. AACP Annual Meeting, August 9-12, 1992, #96.
• Vrahnos, D, Tang, I, Hatoum, HT, Liao, A. Assessment of Clinical Pharmacy Interventions for Dialysis Patients. Winter Practice and Research Forum of ACCP, February 1992.
• Cousins, DH, Hatoum, HT, and Luscombe, DK. Development of Computerized Quality Assurance System for Clinical Pharmacy Services. ASHP Midyear Clinical Meeting, New Orleans, LA. December 1991.
• Lewis, RK, Hatoum, HT, and Hutchinson, RA. Continuity of Pharmaceutical Care in Inpatient and Ambulatory Care Settings. ASHP Midyear Clinical Meeting, New Orleans, December 1991.
• Hatoum, HT. Focus on Illinois Clinicians. Third Annual Dean's Invitational Conference. Program planning member. Speaker on the Economic and Social Cost of Inappropriate Drug Therapy. Panel coordinator for session following presentation, October 1991.
• Hatoum, HT. Pharmaceutical Care as an Issue for the Mexican Pharmacists. An invited speaker at the XXIV Congress of the Mexican Pharmacists Association, Marina Vallarta, Mexico. October 1991.
• Hatoum, HT. The Pharmacoeconomics of Health Care - Where are we? An invited speaker to the College of Pharmacy Practice (UK) and Glaxo Pharmaceuticals (UK) combined meeting at Uxbridge, Middlesex, UK, March 19, 1991.
• Hatoum, HT. The Economic Justification of Clinical Pharmacy Services. An invited speaker to the Department of Pharmacy Practice, University of Wales, March 20, 1991.
• Hatoum, HT. The Role of Economic Justification in Advancing Clinical Pharmacy Services: The U. S. Experience. An invited speaker to the UK College of Clinical Pharmacy meeting in York, UK, March 22, 1991.
• Cousins, DH, Hatoum, HT. Integrating Program Justification and Quality Assurance for Clinical Pharmacy Services. Poster presented at the College of Pharmacy Practice meeting in Uxbridge, Middlesex, U.S., March 191, 1991.
• Hatoum, HT, Kendzierski, D, Lewis, RK, Lundquist, S. Effectiveness of an Inpatient On-Call Resident Program. Poster presentation at ACCP Midyear Clinical Meeting, February 1991.
• Hatoum, HT. The Role of Economic Justification of Clinical Pharmacy Services. Derbyshire Royal Infirmary. Derbyshire, UK, February 1990.
• Hatoum, HT. Issues and Challenges for Pharmacy in the Health Care Systems. An invited speaker addressing the Regulators of Pharmacy during NABP Annual Meeting, Phoenix, Arizona. May 1990.
• Hatoum, HT. The Future of Pharmacy. An invited speaker at ICHP Midyear Meeting (CE Program), Peoria, Illinois. September 1990.
• Lundquist, S, Hutchinson, RA, Hatoum, HT. Productivity Monitoring System for Clinical Pharmacists Activities. ASHP, Midyear Clinical Meeting, Las Vegas, December 1990.
• Hatoum, HT, Witte, KW, and Sherman, JA. Evaluation of the contribution of clinical pharmacists to patient care and cost reduction in one LTC facility. ASCP annual meeting. Chicago, IL. November 1989.
• Lewis, R, Hatoum, HT, and Kendzierski, D. Evaluation of the Effectiveness of an Inpatient On-Call Program Utilizing Pharmacy Residents. ICHP annual meeting. Rosemont, Illinois, April 1989.
• Lundquist, S, Hatoum, HT, and Witte, KW. Utilizing Residents to Solve Medication Related Problems Identified by Distribution Pharmacists. ICHP Annual Meeting. Rosemont, IL. April 1989.
• Hatoum, HT. Member of the Committee on Professional Affairs. ICHP's development network for pharmacy practice programs. ICHP Annual Meeting. Rosemont, IL. April, 1989.
• Witte, KW, and Hatoum, HT. Educational videotaped questions and answers session to be used by the Upjohn Company in training sales representatives "On the Role of Clinical Pharmacists in Drug Selection and Acceptance in Today's Hospital Pharmacy." Summer, 1988.
• Hatoum, HT, Hepler, CD, Witte, KW. Educational Seminar presented to the Ohio Society of Hospital Pharmacists, Ohio Hospital Association. The Economic Justification of Clinical Pharmacy Services. May 10, 1988.
• Hatoum, HT, Hutchinson, RA, Eck, T, and Elliott, LR. Microcosting the Dispensing of Prescriptions in an Outpatient Setting. Abstract presented at the ASHP Midyear Clinical Meeting, December 1987.
• Hatoum, HT. Finding Out the Cost of Intravenous Drug Therapy. Presented at Exhibitor Theater Controlled Release Technologies, Inc. ASHP Midyear Clinical Meeting, Atlanta, Georgia, December 1987.
• Microcosting Unit Dose Dispensing in the 24-hr. Cart Filling. Presented at Travenol ATC 212 Users Conference. ASHP Midyear Clinical Meeting, Atlanta, Georgia, December 1987.
• Hatoum, HT, Witte, KW, and Sherman, J. Reducing the Incidence of Inappropriate Drug Therapy and Drug Cost in Long Term Care Facilities. A grant final report presented at the Governors Conference on Long Term Care, March 1987.
• Hatoum, HT, Witte, KW, and Kaczmarek, E. Staff Productivity and Monitoring, Microcosting Service Functions and Using These Techniques/Data to Justify Pharmacy Services. Vendor's Fair and Educational Expo: Sponsored by the Metropolitan Chicago Health-Care Council, Chicago, IL, September 1986.
• Bertsch, KE, Hatoum, HT, Willett, MS, and Witte, KW. Cost-Justification of Clinical Pharmacy Services on a General Surgery Team: Focus on DRG Cases. Presentation at ACCP Annual Meeting held in Chicago, IL, July 1986.
• Hatoum, HT, Witte, KW, and Sherman, J. Reducing the incidence of Inappropriate Drug Therapy and Drug Cost in Long Term Care Facilities. A grant progress report presented at the Governors Conference on Long Term Care, March 1986.
• Witte, KW, Zeller, F, Hatoum, HT, Klamerus, K, and Bauman, J. Cost Justification of Clinical Pharmacy Services on Three Cardiology Units. Abstract presented at AACP Annual Meeting in Orlando, Florida. July 8, 1985.
• Witte, KW and Hatoum, HT. Specialized Clinical Pharmacy Services - New Approaches for Justification. Presented at A Special Symposium (Travenol) on Achieving Cost-Effectiveness with Clinical Pharmacy Services at the ASHP Midyear Clinical Meeting. 1985.
• Hatoum, HT, Hatoum, NS and Davis, WM. Antagonism of R04-1284-Induced Enhancement of Electroshock Seizures by d-Amphetamine (AM), Several Ring-Substituted Amphetamines and Fenfluramine. Pharmacologist, 22(3): 252 (1980).
• Liao, W, Hatoum, HT, Rappaport, H, Harman, C and Abidi, S. Drug Utilization among the Rural Elderly. Presented at the 1979 meeting of the Mid-South Sociological Association. October-November, 1979.
• Hatoum, HT, Davis, WM, and Braude, MC. Interaction of Amphetamine and 4-Methoxyamphetamine with Agents Altering Central Noradrenergic-Cholinergic Balance. Pharmacologist, 28:135( 1976).
• Waters, IW, Davis, WM, Guinn, MM, Hatoum, HT, Buelke, JL and Braude, MC. Acute Toxicology and Behavioral Effects of Several Methoxyamphetamines in Rodents and Dogs. Pharmacologist, 18:142(1976).
• Davis, WM, Hatoum, HT and Braude, MC. Effects of Mescaline, d-Amphetamine and Two Hallucinogenic Methoxyamphetamines on Conditioned Avoidance in Rats. Pharmacologist, 18:143( 1976).